Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-023923
Filing Date
2016-08-10
Accepted
2016-08-10 16:51:56
Documents
52
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q eigr-10q_20160630.htm 10-Q 1444884
2 EX-31.1 eigr-ex311_7.htm EX-31.1 17087
3 EX-31.2 eigr-ex312_8.htm EX-31.2 17096
4 EX-32.1 eigr-ex321_6.htm EX-32.1 5334
  Complete submission text file 0001564590-16-023923.txt   4750202

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT eigr-20160630.xml EX-101.INS 798081
6 XBRL TAXONOMY EXTENSION SCHEMA eigr-20160630.xsd EX-101.SCH 45263
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eigr-20160630_cal.xml EX-101.CAL 28762
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eigr-20160630_def.xml EX-101.DEF 169251
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20160630_lab.xml EX-101.LAB 339150
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20160630_pre.xml EX-101.PRE 262071
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

EIN.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 161822062
SIC: 2836 Biological Products, (No Diagnostic Substances)